Pharmacists

Partnership to Assist with Cessation of Tobacco (PACT) Level 1 & 2

Fri, Dec 21, 2018

PAS in partnership with CPDPP has updated the Partnership to Assist with Cessation of Tobacco (PACT) Level 1 &2.CPDPP is hosting this course for PAS. 

The training is CPDPP accredited for 4.25 CEUs and is free of charge to all Saskatchewan pharmacists. To access the free training, please email michelle.james@skpharmacists for the sponsorship code.

The PACT program and Tobacco Cessation minor ailment prescribing are complimentary programs but are independent of each other. This means the patient can choose to use the services of either service or both at any time in their process. All pharmacists can provide and submit claims for Bronze Level Services. Only PACT trained pharmacists can provide and submit claims for Bronze Plus, Silver and Gold Level Services, and Follow-ups. If you have further questions on PACT billing or PACT information for pharmacists click here or visit the PACT website.

Please note the training program for the prescribing of tobacco cessation differs from the PACT program and is available in CPDPPs minor ailment training, here.

If you have further questions, please contact the PAS office info@skpharmacists.ca.

Return to list

What's New

Membership Matters

The 2019 PAS Membership and Malpractice Renewal is now open. PAS sent out an email last week to members on how they can renew their PAS membership.

More

An Aging Population, Health care and the Role of Pharmacists in Saskatchewan with a National Comparison

The Pharmacy Association of Saskatchewan, in partnership with CPhA, commissions yearly public opinion surveys on public perceptions and attitudes towards pharmacists in Saskatchewan and across Canada.

More

Update on EpiPen® Availability

There is a recent update from Pfizer Canada on EpiPen® and EpiPen Jr® auto-injectors.

More

Joint CPhA/APhA Statement - Drug Importation Policy

The American Pharmacists Association (APhA) and the Canadian Pharmacists Association (CPhA) have issued a joint statement opposing U.S. federal legislation authorizing personal and commercial importation of prescription drugs from Canada.

More
View All